Suchergebnisse
Suchergebnisse:
Naomi Allen is a Professor in Epidemiology, based in the Clinical Trial Service Unit and Epidemiological Studies Unit. She joined UK Biobank as Senior Epidemiologist in 2011, and became Chief Scientist in 2019, where she is responsible for following-up participants both through linkage with routine health-related datasets, and through web-based ...
Naomi Allen. Professor, University of oxford. Verified email at ndph.ox.ac.uk. Cancer Epidemiology record linkage. Articles Cited by Public access. Title. Sort. Sort by citations Sort by year Sort by title. Cited by. Cited by. Year; UK biobank: an open a ...
- Overview
- Jobs
Download PDF
As an epidemiologist at Oxford University, Naomi Allen was frustrated with the field’s slow progress towards unravelling the causes of disease. Massive and detailed datasets are key to these epidemiological investigations, but large-scale cohorts are hard to access and tend to be disjointed and incomplete. So when a chance to join the UK Biobank arose, she jumped. “Before the launch of the UK Biobank, there wasn't really a large-scale study that provided access to genomic data, lifestyle data and health outcomes all in one place. That was definitely a driver for me, in wanting to help create a resource for the wider research community,” she recalls.
The UK Biobank now delivers just this. First proposed in 2002, it started collecting biological samples and in-depth environmental and lifestyle data from half a million participants in the UK in 2006. Over 30,000 industry and academic researchers worldwide mine this dataset for insight into all aspects of health and disease — analysing whole-exome and whole-genome sequences, biochemical markers, MRI images, health records and more. These researchers have already published 6,000 papers drawing on these data to identify everything from new drug targets to the impact of COVID-19 on the brain. “It's a hard job just to keep up with them all,” says Allen.
Given the size, breadth and depth of the UK Biobank’s longitudinal dataset, its outputs are set to grow exponentially. But its biggest strength is arguably the ease of access to the data, adds Allen. “Without allowing the best minds in the world access to the data, you'll never be able to maximize the utility of it.”
What research findings showcase the drug discovery potential of the UK Biobank?
That's a tough question. Last year alone, there were 1,700 peer-reviewed publications that used data from the UK Biobank. But there are definitely a few key highlights that I would pick out.
Attending Physician (m/f/d)
The Institute of Transfusion Medicine – Transfusion Centre headed by Univ.-Prof. Dr. med. Daniela S. Krause is hiring: Mainz, Rheinland-Pfalz (DE) University of Mainz
NIH Cancer Postdoc Fellowship
Train with world-renowned cancer researchers at NIH? Consider joining the Center for Cancer Research (CCR) at the National Cancer Institute Bethesda, Maryland (US) NIH National Cancer Institute (NCI)
Postdoctoral Fellow (PhD)
Houston, Texas (US) Baylor College of Medicine (BCM)
- Asher Mullard
29. März 2022 · Naomi Allen is someone with a hankering for taking on big challenges. Like selling everything she owned before setting off on a year and a half adventure to 24 countries across 6...
- Threshold Ventures
Hi there! I’m Naomi, co-founder and CEO of Brightline. Our expert care team provides families nationwide with in-network virtual therapy, coaching, and psychiatry for kids and teens.
Professor Naomi Allen. Series. Collecting COVID: Oral Histories. Audio Embed. Georgina Ferry interviews Naomi Allen, Professor in Epidemiology and Chief Scientist at the U.K. Biobank, 6 April 2022.
29. März 2022 · “Our healthcare system is failing our children, which has devastating public health and economic consequences. We simply cannot ignore that fact any longer,” said Naomi Allen, co-founder and CEO of Brightline. “Brightline is the only nationally scaled leader serving this immense need in the market. With this investment, we are ...
